All In Biotech

Drug Trial Radar · NCT01424670

Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis

Last checked: Nov 19, 2026Latest source record: May 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 511 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

511

Actual

Start

Sep 2, 2011

Primary completion

Jul 4, 2016

Study completion Jul 4, 2016

Sponsor

Sponsor type
Industry
First posted
Aug 29, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to determine whether delamanid is effective in the treatment of multidrug-resistant tuberculosis (MDR TB) in combination with other MDR TB medications during 6 months of treatment.

Conditions

  • Multidrug-resistant Tuberculosis

Interventions

  • Delamanid + OBRDrug

    The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.

  • Placebo + OBRDrug

    Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time To Sputum Culture Conversion (SCC) During 6-Month Intensive Period Using The Mycobacteria Growth Indicator Tube (MGIT) SystemTime frame: Month 6

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Tartu, Estonia

  • Site not named

    Riga, Latvia

  • Site not named

    Šiauliai, Lithuania

  • Site not named

    Vilnius, Lithuania

  • Site not named

    Chisinau, Moldova

  • Site not named

    Vorniceni, Moldova

  • Site not named

    Alfonso Ugarte, Peru

  • Site not named

    Comas, Peru

  • Site not named

    El Agustino, Peru

  • Site not named

    Lima Cercado, Peru

  • Site not named

    Makati City, Philippines

  • Site not named

    Quezon City, Philippines

  • Site not named

    Dasmariñas, Cavite, Philippines

  • Site not named

    Quezon City, National Capital Region, Philippines

  • Site not named

    Cape Town, South Africa

  • Site not named

    Durban, South Africa

  • Site not named

    Klerksdorp, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.